Skip to content

    Tilaknagar Inds.

    TI
    Fast Moving Consumer Goods·13 Feb 2026
    Management Summary

    Tilaknagar Industries reported robust Q3 FY26 results, significantly boosted by the Imperial Blue acquisition, which contributed 1.8 million cases in December. Revenue surged 90.5% YoY to Rs. 664 crore, and EBITDA grew 82.3% to Rs. 110 crore. Despite an exceptional expense of Rs. 169 crore related to the acquisition, the company provided positive guidance for future margin expansion and volume growth, aiming for a net debt-to-EBITDA ratio below 1.0x by FY29, while actively managing integration and market challenges.

    Highlights

    5
    • Overall volumes increased by 76.1% YoY to 5.3 million cases in Q3 FY26, with ex-IB volumes up 16.8% to 3.5 million cases.

    • Net Revenue grew 90.5% YoY to Rs. 664 crore in Q3 FY26, and 89.2% adjusted for subsidy.

    • EBITDA grew 82.3% to Rs. 110 crore, with a margin of 16.6% in Q3 FY26.

    • The Imperial Blue acquisition was completed on November 30, 2025, contributing 1.8 million cases in December across India.

    • Company aims for net debt-to-EBITDA ratio below 1.0x by FY29 and expects high-single to low-double digit volume growth for the combined business in FY27.

    Concerns

    4
    • Incurred an exceptional expense of Rs. 169 crore during Q3 FY26 on account of transaction-related costs and TSMA fees.

    • Imperial Blue is expected to witness a low to mid-single digit volume degrowth for the full FY26 due to tepid performance in the 8 months preceding the acquisition.

    • The introduction of Maharashtra-made liquor (MML) has led to a 25% de-growth in the relevant prestige category, impacting Imperial Blue's market environment.

    • Increased receivables from the Telangana government are a matter of concern for the industry, including Tilaknagar.

    Key financials

    Metrics

    8

    Periods

    2

    Q3 FY26

    5
    • Net Revenue
      ₹664 Cr
      YoY+90.5%
    • EBITDA
      ₹110 Cr
      YoY+82.3%
    • EBITDA Margin
      16.6%
    • Overall Volumes
      5.3 Mn
      YoY+76.1%
    • Exceptional Expense
      ₹169 Cr

    9M FY26

    3
    • Net Revenue
      ₹1,471 Cr
      YoY+43.1%
    • EBITDA
      ₹265 Cr
      YoY+50%
    • Overall Volumes
      11.9 Mn
      YoY+40.5%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Gross ₹2,100 crores

    Maturity: 6 years tenure, majority principal due in last year

    M&A

    Imperial Blue

    acquisition · integrated · Consideration ₹NaN (cash)

    Guidance & targets

    8
    CategoryTargetPriority
    Volume
    Imperial Blue Volume Growth
    high-single digit
    High
    Volume
    Imperial Blue Volume Growth
    low to mid-single digit degrowth
    High
    Volume
    Combined Business Volume Growth
    high-single digit to low-double digit
    High
    Volume
    Combined Business Volume Growth
    low-double digit
    High
    Margin
    Combined EBITDA Margins
    expand by 150-250 bps
    High
    Margin
    Imperial Blue Margin Expansion
    250-350 bps
    High
    Debt
    Net Debt-to-EBITDA Ratio
    below 1.0x
    High
    Revenue
    Revenue Growth
    150-200 bps over and above volume growth
    High

    Prag bottling unit commissioning and utilization

    next quarter (Q4 FY26 results)
    CurrentExpected commissioning by Q4 FY26 end, Rs. 10-odd crore investments still to be done.
    TargetCommercial operations and progress towards full utilization.

    Why it matters

    New capacity is crucial for supporting future volume growth and operational efficiency, especially with the Imperial Blue acquisition.

    On CAPEX related to our Prag bottling unit, we are expecting the expanded facility to be commissioned in the 4th quarter of the current fiscal.

    How to verify

    capital_allocation.capex.purposes

    Risks & concerns

    3
    RiskSeverity

    Impact of Maharashtra-made liquor (MML) on prestige category volumes

    The introduction of MML in Maharashtra has led to a 25% de-growth in the relevant prestige category, impacting Imperial Blue, though IB is maintaining market share. The matter is sub-judice.Analyst acknowledged

    medium

    Increased receivables from Telangana government

    The company is facing increased receivables from the Telangana government, a concern shared by the industry, impacting working capital.Analyst acknowledged

    medium

    Imperial Blue volume degrowth for full FY26

    Imperial Blue is expected to witness low to mid-single digit volume degrowth for the full FY26 due to its tepid performance in the 8 months preceding the acquisition.Management acknowledged

    low

    Q&A highlights

    6

    “Yes. 11.7% is Imperial Blue, which is expected to expand by 250 - 350 bps over the next 24 months. And from a combined business perspective, including TI, which till Q2 was doing ~15%, you are looking at 150 - 250 bps expansion.”

    Clarifies the expected margin trajectory for the newly acquired Imperial Blue business and the overall combined entity, providing a key profitability outlook.

    asked by Karan Kamdar

    2 min read5 chapters

    Detailed Narrative

    01

    Imperial Blue Acquisition and Integration Progress

    Tilaknagar Industries successfully completed the acquisition of Imperial Blue on November 30, 2025, for an initial consideration of Rs. 3,442 crore, with an additional EUR 28 million due in FY30. The acquisition immediately boosted Q3 FY26 volumes, with Imperial Blue contributing 1.8 million cases in December alone. The company is actively integrating the business, planning a phase-wise exit from TSMA services by Q4 FY26, and has undertaken organizational restructuring and cost-saving initiatives to realize synergies.

    02

    Strong Q3 FY26 Financial and Volume Performance

    For Q3 FY26, Tilaknagar Industries reported a significant 90.5% YoY increase in net revenue to Rs. 664 crore, and an 82.3% rise in EBITDA to Rs. 110 crore, achieving a 16.6% margin. Overall volumes surged 76.1% YoY to 5.3 million cases, with ex-Imperial Blue volumes growing 16.8% to 3.5 million cases. For the nine months ended December 2025, revenue grew 43.1% to Rs. 1,471 crore, and EBITDA increased 50% to Rs. 265 crore.

    03

    Positive Margin Expansion and Debt Deleveraging Outlook

    Management guided for a substantial expansion in combined EBITDA margins by 150-250 bps over the next 24-36 months, building on Imperial Blue's pre-acquisition margin of 11.7%. The company also aims to reduce its net debt-to-EBITDA ratio to below 1.0x by FY29. This deleveraging is supported by the Rs. 2,100 crore debt taken for the acquisition, which includes a favorable 2-year principal moratorium and a ballooning repayment structure.

    04

    Strategic Growth Initiatives and New Product Launches

    Tilaknagar Industries is leveraging its expanded distribution network, now accessing a 200 million+ cases opportunity in the Indian Alcobev market, to drive premiumization. This strategy includes the recent launch of its luxury whisky, Seven Islands Pure Malt, in Maharashtra, Puducherry, and export markets. The company also plans to organically launch new whisky brands in promising segments and continues to focus on maintaining leadership in the brandy market, positioning itself as a pan-India, pan-category player.

    05

    Operational Updates and Market Challenges

    The expanded Prag bottling unit is on track for commissioning by the end of Q4 FY26, with approximately Rs. 10 crore in remaining investments. However, the company noted an impact from the introduction of Maharashtra-made liquor (MML), which led to a 25% de-growth in the relevant prestige category, though Imperial Blue maintained its market share. Additionally, the company is actively engaging with authorities to resolve increased receivables from the Telangana government, an industry-wide concern.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.